What You Need To Know Regarding Medical Pot This Year

It’s also been studying CBD for use in epilepsy. In 2015, GW Pharma is going to roll out more data that investors will be able to dissect and digest, to see whether or not they want to be long the stock heading into the 2016 election year cycle. Personally, I’m not a huge fan of GW Pharma for 2015 because I think that the stock run last year may have made it a little bit pricy. Douglass: Yes, I think that’s a fair concern.

Traditional valuation is a little tough in health care because earnings per share, as shown by a number of stocks, those can quadruple one year on another. But when you look at their price to sales, for example, for the trailing 12 months, it’s 33 according to Yahoo! Finance.

That is a pretty substantial … that’s priced to perfection, and I think that there are a couple of concerns there. For me, one of the big ones is there’s an election that says, “We’re legalizing marijuana in X state,” and immediately the so-called marijuana stocks get affected, even though these are really going through the FDA.

To read more, visit http://www.nasdaq.com/article/marijuana-stocks-2015-what-you-need-to-know-cm434530

Comments are closed.

Get the latest content first.
©Marijuana Stocks Report